►Management
►Board
of Directors
►Scientific
Advisory Board
►Strategic
Partners
Management
|
 |
Phil Speros, PhD, MBA
Chief Executive Officer
Co-founder of Halsa, holds a Ph.D. from The Johns
Hopkins University in biochemistry, and has four
U.S. Patents. He also holds an MBA from The McCombs
School of Business of The University of Texas at
Austin. Phil has spent nineteen years in
entrepreneurial ventures and technical consulting in
the arena of technology commercialization; he has
founded or co-founded seven previous ventures.
|
|
|
Ken Laderman, PhD
Chief Scientific Officer
Co-founder of Halsa, holds a Ph.D. in molecular
biology from Johns Hopkins, received a postdoctoral
fellowship and research faculty appointment at Cal
Tech, as well as a postdoctoral fellowship at UCLA.
Ken has twelve years of biotechnology experience
with Cetus (acquired by Chiron), Takara (Japan) and
Alpha, and at City of Hope. Ken holds three U.S.
Patents. He has exact domain expertise in cell
culture, protein purification, FDA compliant GLP/GMP
operations, and biologics manufacturing. |
Board of Directors
|
|
David Anderson
Mr. Anderson has more than 20
years of experience as an
executive, advisor and
investor in the life
sciences industry. He is
Chairman of the Board for
both Nanospectra
Biosciences, Inc., a company
developing life science
applications for nanoshells,
a new class of materials,
and PLx Pharma, Inc., a
company developing GI-safer
NSAIDS. From 2001 to 2009,
he was the CEO and Chairman
of the Board of MithraGen, a
cancer vaccine company, and
from 1987 to 2001 was at
Tanox, Inc., serving for 8
years as the Chief
Operations Officer and a
director. He also serves as
an advisor to other early
stage life sciences
companies. Prior to joining
Tanox in 1987, Mr. Anderson
was engaged in the private
practice of law, with a
focus in the areas of
mergers and acquisitions,
financing transactions and
intellectual property
licensing.
|
| |
Guy Diedrich, Ph.D.
Dr. Diedrich is the Vice
Chancellor for The Texas A&M University System
responsible for federal relations, economic
development and technology commercialization. Dr.
Diedrich served for eleven years as President and
CEO of GRA Inc., a software development and
consulting company acquired in 1998 by a
publicly-traded technology company. He also served
as President of Austin Technology Ventures. Dr.
Diedrich serves as a member of the Board of
Directors of the Texas Life Sciences Center,
American Trauma Society, Texas A&M College of
Science, Young President’s Organization, Royal
Economic Society, and Society of Business
Economists. He is a founding member of the Board of
Directors of the Texas Institute for Genomic
Medicine. He is a Ph.D. Candidate at the University
of Cambridge where he is researching the economic
value of trust in organizations as a member of
King’s College.
|
|
 |
Gary Cadenhead, Ph.D.
Chairman
Dr Cadenhead is the director
of the Master of Science in the Science of
Technology Commercialization (MSSTC) Program at the
IC² Institute. Prior to joining The University of
Texas in 1980, Dr. Cadenhead held faculty positions
at Stanford University, UCLA, and the University of
California at Santa Barbara. He graduated Phi Beta
Kappa from Southern Methodist University, earned an
MBA from Harvard University, and received his PhD in
accounting from Stanford University. In 1995, the
Kauffman Foundation and the Entrepreneur of the Year
Institute recognized him as one of the Top Ten
Entrepreneurship Educators of the Year. In a 2003
survey of entrepreneurship directors commissioned by
Entrepreneur magazine, Dr. Cadenhead was recognized
as one of the three top directors of
entrepreneurship programs in the United States. A
CPA licensed in the State of Texas, he had auditing
experience with Deloitte Haskins & Sells, now
Deloitte. He serves on the advisory board of The
Journal of Private Equity.
|
| |
James Cox
Mr. Cox served as Chairman of
the Texas Lottery Commission from 2002 to 2009. He
also served on the Texas General Services Commission
from 1999 to 2002. Cox was president of the Casino
and Aviation Groups of the Estate of Howard Hughes,
and president and CEO of Hydrolab Corporation. He
was previously a Deloitte accounting and auditing
partner. He is a member of the American Institute of
Certified Public Accountants (AICPA) and served on
the Gaming Industry Special Committee, which wrote
the AICPA’s Audit Guide for Casinos. Cox chairs the
board of directors of the Texas Methodist
Foundation. He received bachelor’s and master’s
degrees in business administration from the
University of Texas at Austin, where he also did
doctoral work in American Studies.
|
|
|
Doug Baum
Douglas R. Baum has 18+ years of experience serving in a number of business development and executive management positions within the life sciences industry. Baum is a co-founder and COO of MacuCLEAR Corporation (www.macuclear.com), a specialty clinical stage pharmaceutical company focused on developing a series of compounds for various vascular disorders of the eye. Baum is also a co-founder and sits on the Board of Director’s for Green Dragon Pest Solutions, Inc. (www.greendragonpestsolutions.com) a developer, manufacturer and marketer of organic and all natural pest control products.
Mr. Baum previously served as Vice President, Global Corporate Development at Premier Research Group (PRG), Inc. a global contract research organization serving the pharmaceutical, biotechnoogy and medical device industries. In 2006 PRG acquired SCIREX Corporation where Mr. Baum served as Executive Vice President & General Manager, Early Drug Development where he was responsible for all strategic, commercial, organizational and financial aspects of SCIREX's Early Development business unit. Prior to this Mr. Baum lead the Business Development and Strategy functional area within SCIREX, which at the time was wholly owned by Omnicom Group, a Fortune 400 company (NYSE: OMC). Mr. Baum has worked on the development of 17 FDA approved products (pharmaceuticals and medical devices) and has authored/presented study results from over 15 pivotal clinical trials at various scientific meetings throughout the US, Europe and Australia.
Mr. Baum obtained his Bachelor's of Business Administration degree from the McCombs Business School at the University of Texas at Austin (UT), as well as, a Master’s of Science in Technology Commercialization degree from UT. Baum began his career in an international position living and working in Japan.
|
Scientific
Advisory Board
|
 |
John Foreyt, Ph.D.
Dr. Foreyt is a Professor in
the Department of Medicine and the Department of
Psychiatry and Behavioral Sciences at Baylor College
of Medicine, Houston, Texas. He also is the Director
of the DeBakey Heart Center's Behavioral Medicine
Research Center. Dr Foreyt received his B.S. in
psychology from the University of Wisconsin and his
M.S. and Ph.D.in clinical psychology in 1969 from
Florida State University. He has served as a member
of the National Task Force on the Prevention and
Treatment of Obesity, National Institutes of Health;
The Committee to Develop Criteria for Evaluating the
Outcomes of Approaches to Prevent and Treat Obesity,
Food and Nutrition Board, Institute of Medicine,
National Academy of Sciences; and The Expert Panel
on the Identification, Evaluation, and Treatment of
Adults at High Risk for Cardiovascular Disease,
National Institutes of Health, NHLBI. He is
currently a member of the editorial boards of:
Eating Disorders; Obesity Research; Journal of
Cardiopulmonary Rehabilitation; American Journal of
Health Promotion; Journal of Behavioral Medicine;
American Journal of Health Promotion; and Diabetes,
Obesity and Metabolism. Dr. Foreyt has published
extensively in the areas of diet modification,
cardiovascular risk reduction, eating disorders, and
obesity. He has published 17 books and more than 260
articles.
|
|
 |
Theresa Fossum, DVM
Dr Fossum is currently the
Associate Professor and Chief of Surgery at the
Department of Small Animal Medicine and Surgery at
the College of Veterinary Medicine, Texas A&M
University and Director of the Texas Institute of
Preclinical Studies (TIPS). Dr Fossum is a graduate
of Washington State University, where she obtained
her Doctor in Veterinary Medicine degree in 1982. Dr
Fossum also obtained her Masters in Surgery in 1986
at the Ohio State University, Columbus. After
completing two degrees, she continued her studies
and completed her Ph.D at the Texas A&M University,
in 1992. Dr Fossum has spent many years studying in
the United States and now and specializes in Small
Animal Surgery. She is currently involved with many
research funding projects including In vivo
evaluation of the DeBakey ventricular assist device
in a sheep model. Dr Fossum is the editor of Small
Animal Surgery, and has written more than one
hundred articles, for various journals.
|
|
 |
Professor Michael J. Tisdale
Dr Tisdale is a world-renowned
cancer and metabolic disease researcher who
graduated from Hull University in 1967 with a BSc (lst
Class Honours) (Chemistry), followed by a PhD
(Chemistry), from London, 1970 and a DSc (Cancer
Biochemistry), London, 1983. He joined the Cancer
Research Campaign Experimental Chemotherapy Group in
the Department of Pharmacy at Aston University as
Senior Research Fellow in October 1980. Prior to
that , Dr Tisdale spent 8 years as Lecturer in the
Department of Biochemistry at St Thomas’s Hospital
Medical School, University of London, one year as
Scientific Officer at Rothamstead Experimental
Station, Harpenden and one year as MRC Fellow at the
Institute of Cancer Research. Dr Tisdale’s research
focuses include: cancer cachexia, its mechanism and
treatment and the treatment of obesity and type 2
diabetes.
|
|
 |
Robert Kramer, M.D.
Presently: SENIOR MEDICAL ADVISOR, NTEC Biotechnology Incubator, Frisco, Texas, CHIEF MEDICAL OFFICER, Nutritox, Inc; TelaDoc, Inc.; Imadulation/Sound Solutions for Health, Inc., CORPORATE MEDICAL DIRECTOR, Zale Corporation, Texas Industries, Wyndham International, Prentiss Properties; ACS, Inc., Perot Systems, Brinker International, CONSULTANT PHYSICIAN; Dallas Museum of Art, Dallas Theater Center, Dallas Symphony, Dallas Opera, Dallas Childrens’ Theater, Dallas Children’s Museum, Hotel Crescent Court, Ritz Carlton Hotel Dallas, CONSULTANT, International Center for Toxicology and Medicine and Member of Mold-Medicine Scientific Group, BOARD or MEDICAL ADVISORY BOARD: Department of Biomedical Engineering, UT Austin; Gryphon Technologies, Inc;SenoMedical Systems, Patton Surgical Instruments, Secure Symbology, Inc; Veroscan, Inc; Encentuate, Inc; Torquin LLC; CareGain, Inc; Medical Present Value; TelaDoc, Inc.; Delphi Health Systems, Inc; NTEC; BMSI; TotalChart, Inc; Pardalis, Inc; Holocaust Studies Program, UT Dallas; St. Marks School of Texas; Reading and Radio Resource; Home Health Services of Dallas; Texas Healthcare & Bioscience Institute Foundation (THBI);
Previously: CLINICAL PROFESSOR OF PEDIATRICS AND PULMONOLOGY, UT Southwestern Medical Center (Ret.), CHAIRMAN, Department of Pediatrics , Baylor University Medical Center, (Ret.), DISTINGUISHED ADJUNCT PROFESSOR, University of Dallas, Graduate School of Management, FELLOW, AMERICAN ACADEMY OF PEDIATRICS, Member Pulmonology Section, DIPLOMATE, American Board of Pediatrics. MEMBER, American Association for the Advancement of Science; New York Academy of Science, FOUNDING PARTNER, Pediatric Associates of Dallas; Baylor Pediatric Center, DISTINGUISHED FELLOW, ICC Institute, McCombs Business School, UT Austin. Medical Director of the Health Care Consulting Practice, Coopers and Lybrand,Founding Partner, DecisionHealth Consultancy; Director of Life Sciences, Technological Partners; Distinguished Adjunct Professor, University of Dallas Graduate School of Management; Founding Partner, Pediatric Associates of Dallas; Baylor Pediatric Center; Faculty at UT Southwestern Medical Center. Board Membership: Itasca Ventures; the Hockaday School; Brown University Alumni Trustee; Susan Komen Foundation; National Cystic Fibrosis Foundation Research and Development Council;
|
Strategic Partners
Halsa
believes strategic alliances can augment product
development and advance projects towards
commercialization. For more information regarding
partnership opportunities, please contact us:
alliance@halsapharma.net |
